WO2016104490A1 - 新規な敗血症治療剤及び/又はそのスクリーニング方法 - Google Patents
新規な敗血症治療剤及び/又はそのスクリーニング方法 Download PDFInfo
- Publication number
- WO2016104490A1 WO2016104490A1 PCT/JP2015/085806 JP2015085806W WO2016104490A1 WO 2016104490 A1 WO2016104490 A1 WO 2016104490A1 JP 2015085806 W JP2015085806 W JP 2015085806W WO 2016104490 A1 WO2016104490 A1 WO 2016104490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arid5a
- antibody
- expression
- sepsis
- substance
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a novel therapeutic agent for sepsis and / or a screening method thereof.
- Sepsis is a disease characterized by a systemic inflammatory response syndrome caused by a pathogen. Sepsis manifests symptoms such as fever, tachypnea, tachycardia, leukocytosis, etc. If progressed, consciousness, circulatory insufficiency such as decreased blood pressure, and organ dysfunction such as renal, lung, liver, and coagulation dysfunction . If severe, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation syndrome (DIC), etc. may occur, leading to cardiac arrest and death due to septic shock. As sepsis progresses, the prognosis worsens and the mortality rate increases, so it is necessary to conduct early diagnosis and treatment at the earliest possible stage.
- ARDS acute respiratory distress syndrome
- DIC disseminated intravascular coagulation syndrome
- Septic shock is a severe sepsis that involves organ hypoperfusion and hypotension that are largely unresponsive to early fluid composition, most of which is caused by nosocomial gram-negative or gram-positive cocci. Septic shock often occurs in immunocompromised patients, patients with chronic and debilitating diseases, with an average mortality rate of about 40%.
- antibiotics for the purpose of suppressing the production of lipopolysaccharide (LPS) and nonsteroidal anti-inflammatory drugs for suppressing inflammatory reactions are performed.
- LPS lipopolysaccharide
- Sepsis is understood to occur as a result of complex interactions between infection-causing bacteria and the patient's immunity, inflammation and coagulation system. Organ failure resulting from sepsis is believed to cause host organ damage by amplifying the patient's response to infection-causing bacteria. Therefore, it has been investigated as a therapeutic agent for sepsis by antagonists to TNF- ⁇ , IL-6, etc., which are inflammatory cytokines that are greatly involved in the inflammatory response of patients. (For example, see Non-Patent Documents 1 and 2). There is a need for the development of a more effective treatment method for sepsis and septic shock for which a reliable therapeutic agent has not yet been developed despite the high mortality rate.
- AT rich interactive domain 5A (AT Rich Interactive Domain 5A, hereinafter abbreviated as Arid5A) has been reported as a stabilized protein of IL-6 mRNA (see, for example, Non-Patent Document 3).
- An object of the present invention is to provide a more effective therapeutic agent for sepsis and / or septic shock, and a screening method thereof.
- the present invention includes the following.
- a therapeutic agent for sepsis and / or septic shock comprising an Arid5A inhibitor as an active ingredient.
- Arid5A inhibitor is one or more substances selected from the group consisting of a nucleic acid oligo and an Arid5A antibody.
- the nucleic acid oligo is an oligo composed of natural and non-natural RNA or DNA.
- a screening method for candidate substances useful for treatment of sepsis and / or septic shock comprising: (A) a step of evaluating the influence of the test substance on the expression and / or function of Arid5A, and (b) a process of selecting a substance that decreases the expression and / or function of Arid5A compared to the case where the test substance is not used.
- a method comprising: [5] A screening method for a candidate substance useful for the treatment of sepsis and / or septic shock according to [4], wherein the method comprises: (A) a step of evaluating the effect of the test substance on the expression of Arid5A, and (b) a process of selecting a substance that decreases the expression of Arid5A as compared with the case where the test substance is not used.
- a method comprising: [6] A screening method for a candidate substance useful for the treatment of sepsis and / or septic shock according to [4], the method comprising: (A) a step of administering a test substance to an experimental animal; (B) measuring the effect on the expression of Arid5A by PCR, and (c) selecting a substance that decreases Arid5A compared to the case where the test substance is not administered to an experimental animal,
- a method comprising: [7] A screening method for a candidate substance useful for the treatment of sepsis and / or septic shock according to [4], wherein the method comprises: (A) evaluating the influence of the test substance on the function of Arid5A, and (b) selecting a substance that reduces the function of Arid5A compared to the case where the test substance is not used.
- a method comprising: [8] The method for screening a candidate substance useful for the treatment of sepsis and / or septic shock according to [7], wherein the function of Arid5A is stabilization of IL-6 mRNA. [9] A method for treating sepsis and / or septic shock, comprising administering an Arid5A inhibitor. [10] An Arid5A inhibitor for use in the treatment of sepsis and / or septic shock. [11] Use of an Arid5A inhibitor for the manufacture of a therapeutic agent for sepsis and / or septic shock.
- the therapeutic agent for sepsis and / or septic shock according to the present invention has a high therapeutic effect on sepsis and / or septic shock.
- the present invention can provide a screening method for a therapeutic agent exhibiting a high therapeutic effect.
- Arid5A-deficient mice (A) Upper: wild-type Arid5A allele, middle: targeting vector, lower: expected mutant allele. The major part of the DNA binding domain is replaced with Neo-cassette with both ends sandwiched by loxp sequences. (B) Genotype analysis by Southern blotting analysis; wild type (+ / +), heterozygous type (+/-). It is a graph which shows the 7-day survival rate by a septic shock model. It is the graph which quantified the mRNA level of Arid5A in a macrophage cell line by qPCR. It is the graph which identified the density
- 2 is a graph in which the concentration of TNF- ⁇ in the culture supernatant of a macrophage cell line is specified by an ELISA method. It is the graph which showed the expression of mRNA of Arid5A in a peritoneal macrophage. It is the graph which showed the expression of mRNA of IL-6 in a peritoneal macrophage. 2 is a graph showing the expression of TNF- ⁇ mRNA in peritoneal macrophages.
- the present invention relates to a therapeutic agent for sepsis and / or septic shock, and a screening method thereof.
- the therapeutic agent for sepsis and / or septic shock of the present invention comprises an Arid5A inhibitor as an active ingredient.
- Arid5A in the present invention refers to AT rich interactive domain 5A (AT Rich Interactive Domain 5A, hereinafter abbreviated as “Arid5A”), and is reported as a stabilizing protein of IL-6 mRNA.
- human Arid5A includes various isoforms (NCBI accession numbers NP997646.1, XP0067122666.1, XP0067122655.1, XP005263918.1, XP005263913.1, XP0052639.17.1, etc.).
- various isoforms are also included for mouse Arid5A (NCBI accession numbers NP00165676.1, NP00165677.1, NP0012775655.1, NP0012777656.1, NP666108.2, etc.).
- the “Arid5A inhibitor” refers to a substance that inhibits the expression of Arid5A and / or a substance that inhibits the function of Arid5A.
- the Arid5A inhibitor may be a substance that directly inhibits Arid5A expression itself, or may be a substance that binds to a molecule affected by Arid5A (such as IL-6 mRNA) and indirectly inhibits the biological function of Arid5A.
- a substance that inhibits stabilization of IL-6 mRNA by binding to IL-6 mRNA competitively with Arid5A can be mentioned.
- human IL-6 mRNA includes various isoforms (NCBI accession numbers NM000000600.3, XM005249745.2, etc.).
- mouse IL-6 mRNA includes various isoforms (NCBI accession number NM031168.1, etc.).
- Examples of the Arid5A inhibitor in the present invention include, but are not particularly limited to, low molecular weight substances such as anti-Arid5A antibodies, nucleic acid oligos, and chlorpromazine.
- Preferable examples of the Arid5A inhibitor of the present invention include at least one selected from the group consisting of a nucleic acid oligo and an Arid5A antibody, more preferably a nucleic acid oligo, and still more preferably siRNA.
- RNA interference is a method (Genes and Development, 16, 948-958 (2002)) reported as a method for suppressing gene expression using RNA, and has a double or double sequence having the same or similar sequence as the target gene.
- strand RNA is introduced into a cell, the expression of the introduced foreign gene and target endogenous gene is both reduced.
- the expression of the Arid5A gene can be inhibited using siRNA or antisense nucleic acid that exhibits an RNA interference effect on the expression of the Arid5A gene.
- nucleic acid oligo in the present invention is an oligo composed of natural and non-natural RNA or DNA, and means an oligomer of nucleic acid that controls the function of the Arid5A gene or protein.
- the nucleic acid oligo in the present invention includes siRNA, shRNA, antisense nucleic acid, decoy nucleic acid, and nucleic acid aptamer.
- the nucleic acid oligo in the present invention includes siRNA or shRNA, and more preferably siRNA.
- siRNA means a double-stranded RNA consisting of short strands that are not toxic to cells, for example, 15 to 49 base pairs, preferably 15 to 35 base pairs, and more preferably 21 to 30 base pairs. It can be.
- ShRNA is RNA in which single-stranded RNA constitutes a double strand through a hairpin structure.
- SiRNA and shRNA need not be completely identical to the target gene, but have at least 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more sequence homology.
- the portion of double-stranded RNA in which the RNAs in siRNA and shRNA are paired is not limited to a perfect pair, but mismatch (corresponding base is not complementary), bulge (base corresponding to one strand) Etc.) may include an unpaired portion.
- both bulges and mismatches may be contained in the double-stranded RNA region where the RNAs in the dsRNA pair with each other.
- the “antisense nucleic acid” in the present invention is an antisense nucleic acid complementary to a transcription product of DNA encoding Arid5A. There are several factors as described below for the action of an antisense nucleic acid to suppress the expression of a target gene.
- the antisense sequence used in the present invention may suppress the expression of the target gene by any of the actions described above.
- an antisense sequence complementary to the untranslated region near the 5 'end of Arid5A mRNA is designed, it is considered effective for inhibiting translation of the gene.
- sequences complementary to the coding region or the 3 'untranslated region can also be used.
- a translation region of a gene but also a sequence complementary to an untranslated region can be used.
- the nucleic acid containing the antisense sequence of the sequence of an untranslated region is included in the antisense nucleic acid used in the present invention.
- the antisense nucleic acid preferably has a complementarity of 90% or more, most preferably 95% or more, to the transcription product of the target gene.
- the length of the antisense RNA that effectively inhibits the expression of the target gene using the antisense sequence is not particularly limited.
- the “decoy nucleic acid” in the present invention is a nucleic acid oligo having homology with the IL-6 mRNA sequence recognized by Arid5A. Instead of IL-6 mRNA sequence, it binds to Arid5A and inhibits the function of Arid5A.
- the “nucleic acid aptamer” in the present invention is a nucleic acid encoding a stem loop region present in IL-6 3′UTR or a similar nucleic acid.
- the “anti-Arid5A antibody” in the present invention can be obtained as a polyclonal antibody or a monoclonal antibody using known means.
- the origin of the antibody used in the present invention is not particularly limited, but is preferably derived from a mammal, more preferably a human-derived antibody.
- Mammal-derived monoclonal antibodies include those produced by hybridomas and those produced by hosts transformed with expression vectors containing antibody genes by genetic engineering techniques. This antibody inhibits the functional expression of Arid5A by binding to Arid5A.
- Antibody-producing hybridomas can basically be prepared as follows using known techniques. That is, using Arid5A as a sensitizing antigen, this is immunized according to a normal immunization method, and the resulting immune cells are fused with a known parent cell by a normal cell fusion method, and monoclonal antibodies are obtained by a normal screening method. It can be produced by screening antibody-producing cells.
- the anti-Arid5A antibody can be prepared as follows.
- human Arid5A used as an antigen for obtaining an antibody can be obtained by using the Arid5A gene / amino acid sequence disclosed in known literature.
- Arid5A The gene sequence of Arid5A is inserted into a known expression vector system to transform an appropriate host cell, and then the desired Arid5A protein is purified from the host cell or culture supernatant by a known method. What is necessary is just to use Arid5A protein as a sensitizing antigen.
- An Arid5A protein prepared by chemical synthesis may also be used as a sensitizing antigen.
- the mammal to be immunized with the sensitizing antigen is not particularly limited, but is preferably selected in consideration of compatibility with the parent cell used for cell fusion. Animals such as mice, rats, hamsters and the like are used.
- Immunization of animals with a sensitizing antigen is performed according to a known method.
- a sensitizing antigen is injected intraperitoneally or subcutaneously into a mammal.
- the sensitizing antigen is diluted to an appropriate amount with PBS (Phosphate-Buffered Saline), physiological saline, etc. and suspended, and if necessary, an appropriate amount of an ordinary adjuvant such as Freund's complete adjuvant is mixed and emulsified. It is preferred to administer several times every 4 to 21 days.
- an appropriate carrier can be used during immunization with the sensitizing antigen.
- immune cells are removed from the mammal and subjected to cell fusion.
- Spleen cells are particularly preferred as preferable immune cells to be subjected to cell fusion.
- Mammalian myeloma cells as the other parent cells to be fused with the immune cells are already known in various cell lines such as P3X63Ag8.653 (J. Immunol. 123, 1548-1550 (1979)). Used as appropriate.
- the cell fusion of the immunocytes and myeloma cells can be basically performed according to a known method, for example, the method of Milstein et al. (Methods Enzymol., 73, 3-46 (1981)).
- the cell fusion is performed, for example, in a normal nutrient culture medium in the presence of a cell fusion promoter.
- a cell fusion promoter for example, polyethylene glycol (PEG), Sendai virus (HVJ), or the like is used as the fusion accelerator, and an auxiliary agent such as dimethyl sulfoxide can be added and used to increase the fusion efficiency as desired.
- the usage ratio of immune cells and myeloma cells is preferably 1 to 10 times that of myeloma cells.
- the culture solution used for the cell fusion for example, RPMI1640 culture solution suitable for growth of the myeloma cell line, MEM culture solution, and other normal culture solutions used for this kind of cell culture can be used.
- Serum supplements such as fetal calf serum (FCS) can be used in combination.
- a predetermined amount of the immune cells and myeloma cells are mixed well in the culture solution and heated to about 37 ° C. in advance, for example, a PEG solution having an average molecular weight of about 1000 to 6000 is usually 30
- the target fused cell is formed by adding and mixing at a concentration of ⁇ 60% (w / v). Subsequently, cell fusion agents and the like that are undesirable for the growth of the hybridoma can be removed by adding an appropriate culture solution successively and centrifuging to remove the supernatant.
- the hybridoma is selected by culturing in a normal selective culture solution such as a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). Culturing with the HAT culture solution is continued for a time sufficient for the cells other than the target hybridoma (non-fused cells) to die, usually several days to several weeks. Then, a normal limiting dilution method is performed to screen and clone hybridomas that produce the target antibody.
- a normal selective culture solution such as a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). Culturing with the HAT culture solution is continued for a time sufficient for the cells other than the target hybridoma (non-fused cells) to die, usually several days to several weeks. Then, a normal limiting dilution method is performed to screen and clone hybridomas that produce the target antibody.
- human lymphocytes are sensitized in vitro with the desired antigen protein or antigen-expressing cells, and sensitized B lymphocytes are human myeloma cells such as U266.
- a desired human antibody having a binding activity to a desired antigen or antigen-expressing cells can be obtained (see Japanese Patent Publication No. 1-59878).
- antigens or antigen-expressing cells may be administered to a transgenic animal having a repertoire of human antibody genes, and a desired human antibody may be obtained according to the method described above (see International Patent Application Publication No. WO93 / 12227, etc.).
- the hybridoma producing the monoclonal antibody thus produced can be subcultured in a normal culture solution and can be stored for a long time in liquid nitrogen.
- the hybridoma is cultured according to a normal method and obtained as a culture supernatant, or the hybridoma is administered to a mammal compatible therewith to proliferate, A method of obtaining ascites is employed.
- the former method is suitable for obtaining highly pure antibodies, while the latter method is suitable for mass production of antibodies.
- a recombinant antibody produced by cloning an antibody gene from a hybridoma, incorporating it into an appropriate vector, introducing it into a host, and producing it using a gene recombination technique can be used.
- a recombinant antibody produced by cloning an antibody gene from a hybridoma incorporating it into an appropriate vector, introducing it into a host, and producing it using a gene recombination technique
- a recombinant antibody produced by cloning an antibody gene from a hybridoma, incorporating it into an appropriate vector, introducing it into a host, and producing it using a gene recombination technique.
- mRNA encoding the variable (V) region of the antibody is isolated from a cell producing the target antibody, for example, a hybridoma. Isolation of mRNA may be performed by a known method such as guanidine ultracentrifugation (Chirgwin, JM et al., Biochemistry (1979) 18, 5294-5299), AGPC method (Anal. Biochem. (1987) 162, 156-159) etc. to prepare total RNA, and mRNA is prepared using mRNA Purification Kit (manufactured by Pharmacia). Alternatively, mRNA can be directly prepared by using QuickPrep mRNA Purification Kit (Pharmacia).
- the antibody V region cDNA is synthesized from the obtained mRNA using reverse transcriptase.
- the synthesis of cDNA can be performed using AMV Reverse Transscriptase First-strand cDNA Synthesis Kit or the like.
- 5'-Ampli FINDER RACE Kit (Clontech) and 5'-RACE method using PCR (Frohman, M. A. et al., Proc. Natl. Acad. Sci.) are used for cDNA synthesis and amplification. USA (1988) 85, 8998-9002; Belyavsky, A. et al., Nucleic Acid Res. (1989) 17, 2919-2932).
- the target DNA fragment is purified from the obtained PCR product and ligated with vector DNA. Further, a recombinant vector is prepared from this, introduced into Escherichia coli, etc., and colonies are selected to prepare a desired recombinant vector.
- the base sequence of the target DNA is confirmed by a known method such as the deoxy method.
- DNA encoding the desired antibody V region is obtained, it is ligated with DNA encoding the desired antibody constant region (C region) and incorporated into an expression vector.
- DNA encoding the V region of the antibody may be incorporated into an expression vector containing DNA of the antibody C region.
- an antibody gene is incorporated into an expression vector so as to be expressed under the control of an expression control region, for example, an enhancer or a promoter, as described later.
- an expression control region for example, an enhancer or a promoter, as described later.
- host cells can be transformed with this expression vector to express the antibody.
- a recombinant antibody that has been artificially modified for the purpose of reducing xenoantigenicity to humans such as a chimeric antibody, a humanized antibody, a human antibody, etc.
- modified antibodies can be produced using known methods.
- a chimeric antibody is obtained by ligating the DNA encoding the antibody V region obtained as described above with DNA encoding the human antibody C region, incorporating it into an expression vector, introducing it into a host, and producing it (See European Patent Application Publication No. EP 125023, International Patent Application Publication No. WO 92-19759). Using this known method, a chimeric antibody useful in the present invention can be obtained.
- a humanized antibody is also called a reshaped human antibody or a humanized antibody, and a complementarity determining region (CDR) of a non-human mammal, for example, a mouse antibody, is transplanted to the complementarity determining region of a human antibody.
- CDR complementarity determining region
- the general gene recombination technique is also known (see European Patent Application Publication No. EP125023, International Patent Application Publication No. WO92-19759).
- oligonucleotides were prepared so that the DNA sequence designed to link the CDR of the mouse antibody and the framework region (FR) of the human antibody had an overlapping portion at the end. It is synthesized from nucleotides by PCR. It is obtained by ligating the obtained DNA with DNA encoding the human antibody C region, then incorporating it into an expression vector, introducing it into a host and producing it (European Patent Application Publication No. EP239400, International Patent Application Publication No. WO92). -19759).
- the FR of the human antibody to be linked via CDR one that forms a favorable antigen binding site in the complementarity determining region is selected. If necessary, the amino acid in the framework region of the variable region of the antibody may be substituted so that the complementarity determining region of the reshaped human antibody forms an appropriate antigen-binding site (Sato, K. et al., Cancer). Res. (1993) 53, 851-856).
- the human antibody C region is used for the chimeric antibody and the humanized antibody.
- Examples of the human antibody C region include C ⁇ , and for example, C ⁇ 1, C ⁇ 2, C ⁇ 3, or C ⁇ 4 can be used.
- the human antibody C region may be modified in order to improve the stability of the antibody or its production.
- the chimeric antibody is composed of a variable region of a non-human mammal-derived antibody and a C region derived from a human antibody, and the humanized antibody is a complementarity determining region of a non-human mammal-derived antibody, a framework region and a C region derived from a human antibody Since the antigenicity in the human body is reduced, it is useful as an antibody used in the present invention.
- variable region of a human antibody can be expressed as a single chain antibody (svFv) on the surface of the phage by the phage display method, and a phage that binds to the antigen can be selected.
- svFv single chain antibody
- the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. If the DNA sequence of scFv that binds to the antigen is clarified, an appropriate expression vector of the sequence can be prepared and a human antibody can be obtained.
- the antibody gene constructed as described above can be expressed and obtained by a known method.
- it can be expressed by a commonly used useful promoter, an antibody gene to be expressed, a DNA in which a poly A signal is operably linked to the 3 'downstream side thereof, or a vector containing the same.
- a promoter / enhancer a human cytomegalovirus early promoter / enhancer (human cytomegalovirus immediate early promoter / enhancer) can be mentioned.
- viral promoters / enhancers such as retrovirus, polyomavirus, adenovirus, simian virus 40 (SV40), and human elongation factor 1 ⁇ (HEF1 ⁇ ).
- a promoter enhancer derived from mammalian cells such as the above may be used.
- Escherichia coli it can be expressed by functionally combining a commonly used useful promoter, a signal sequence for antibody secretion, and an antibody gene to be expressed.
- the promoter include lacZ promoter and araB promoter.
- the lacZ promoter the method of Ward et al. (Ward, ES et al., Nature (1989) 341, 544-546; Ward, ES et al., FASEB J. (1992) 6, 2422-2427), when using the araB promoter, the method of Better et al. (Better, M. et al., Science (1988) 240, 1041-1043) may be used.
- the pe1B signal sequence As a signal sequence for antibody secretion, the pe1B signal sequence (Lei, SP et al., J. Bacteriol. (1987) 169, 4379-4383) may be used when it is produced in the periplasm of E. coli. . After separating the antibody produced in the periplasm, the structure of the antibody is appropriately refolded and used (see, for example, WO 96/30394).
- the origin of replication those derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and the like can be used. Further, for the purpose of gene copy number amplification in the host cell system, the expression vector is used as a selection marker.
- An aminoglycoside phosphotransferase (APH) gene, a thymidine kinase (TK) gene, an E. coli xanthine guanine phosphoribosyltransferase (Ecogpt) gene, a dihydrofolate reductase (dhfr) gene and the like can be included.
- Production systems for antibody production include in vitro and in vivo production systems.
- in vitro production systems include production systems using eukaryotic cells and production systems using prokaryotic cells.
- animal cells When eukaryotic cells are used, there are production systems using animal cells, plant cells, or fungal cells.
- animal cells include (1) mammalian cells such as CHO, COS, myeloma, BHK (baby hamster kidney), Hela, Vero, etc. (2) amphibian cells such as Xenopus oocytes, or (3) Insect cells such as sf9, sf21, and Tn5 are known.
- plant cells cells derived from Nicotiana tabacum are known and may be cultured in callus.
- fungal cells examples include yeasts such as Saccharomyces, such as Saccharomyces cerevisiae, and filamentous fungi such as Aspergillus, such as Aspergillus aspergillus.
- yeasts such as Saccharomyces, such as Saccharomyces cerevisiae
- filamentous fungi such as Aspergillus, such as Aspergillus aspergillus.
- prokaryotic cells there are production systems using bacterial cells.
- Known bacterial cells include Escherichia coli (E. coli) and Bacillus subtilis.
- An antibody can be obtained by introducing a desired antibody gene into these cells by transformation, and culturing the transformed cells in vitro. Culture is performed according to a known method. For example, DMEM, MEM, RPMI 1640, and IMDM can be used as a culture solution, and a serum supplement such as fetal calf serum (FCS) can be used in combination.
- the antibody may be produced in vivo by transferring the cell into which the antibody gene has been introduced into the peritoneal cavity of the animal.
- examples of in vivo production systems include production systems using animals and production systems using plants. When animals are used, there are production systems using mammals and insects.
- an antibody gene is introduced into these animals or plants, and the antibodies are produced and collected in the animals or plants.
- an antibody gene is inserted in the middle of a gene encoding a protein inherently produced in milk such as goat ⁇ -casein and adjusted as a fusion gene.
- a DNA fragment containing the fusion gene into which the antibody gene has been inserted is injected into a goat embryo, and the embryo is introduced into a female goat.
- the desired antibody is obtained from the milk produced by the transgenic goat obtained from the goat that received the embryo or its progeny.
- hormones may be used in the transgenic goat as appropriate (Ebert, KM et al., Bio / Technology (1994) 12 699-702).
- silkworms When silkworms are used, silkworms are infected with baculovirus into which the antibody gene of interest is inserted, and desired antibodies are obtained from body fluids of these silkworms (Maeda, S. et al., Nature (1985) 315, 592-594). ). Further, when tobacco is used, the target antibody gene is inserted into a plant expression vector such as pMON530, and this vector is introduced into a bacterium such as Agrobacterium tumefaciens. This bacterium is infected with tobacco, for example, Nicotiana tabacum, and a desired antibody is obtained from the leaves of this tobacco (Julian, K.-C. Ma et al., Eur. J. Immunol. (1994) 24, 131-138). .
- DNAs encoding the antibody heavy chain (H chain) or light chain (L chain) are separately incorporated into an expression vector and simultaneously transformed into the host.
- the host may be transformed by incorporating DNAs encoding H and L chains into a single expression vector (see International Patent Application Publication No. WO94-11523).
- the antibody produced and expressed as described above can be separated from the inside and outside of the cell and from the host and purified to homogeneity. Separation and purification of the antibody used in the present invention can be performed by affinity chromatography.
- Examples of the column used for affinity chromatography include a protein A column and a protein G column.
- Examples of the carrier used for the protein A column include HyperD, POROS, Sepharose F., and the like. F etc. are mentioned.
- the antibodies used in the present invention can be separated and purified by appropriately selecting and combining chromatography, filters, ultrafiltration, salting out, dialysis and the like other than the affinity chromatography.
- chromatography include ion exchange chromatography, hydrophobic chromatography, gel filtration, and the like. These chromatography methods can be applied to HPLC (high performance liquid chromatography). Moreover, you may use reverse phase HPLC (reverse phase HPLC).
- the concentration of the antibody obtained above can be measured by measuring absorbance, ELISA, or the like. That is, in the case of measuring the absorbance, after appropriately diluting with PBS ( ⁇ ), the absorbance at 280 nm is measured, and 1 mg / ml is calculated as 1.350D.
- the measurement can be performed as follows. That is, 100 ⁇ l of goat anti-human IgG (manufactured by TAG) diluted to 1 ⁇ g / ml with 0.1 M bicarbonate buffer (pH 9.6) was added to a 96-well plate (manufactured by Nunc) and incubated at 4 ° C. overnight. Is immobilized. After blocking, 100 ⁇ l of appropriately diluted antibody used in the present invention or a sample containing the antibody, or human IgG (manufactured by CAPPEL) as a standard is added, and incubated at room temperature for 1 hour.
- the antibody used in the present invention may be a conjugated antibody bound to various molecules such as polyethylene glycol (PEG), radioactive substances, and toxins. Such a conjugated antibody can be obtained by chemically modifying the obtained antibody. Antibody modification methods have already been established in this field.
- the “antibody” in the present invention includes these conjugated antibodies.
- the antibody of the present invention includes not only a bivalent antibody typified by IgG but also a monovalent antibody or a multivalent antibody typified by IgM as long as it binds to Arid5A.
- the multivalent antibodies of the present invention include multivalent antibodies that all have the same antigen-binding site, or multivalent antibodies that have some or all different antigen-binding sites.
- the antibody of the present invention may be a bispecific antibody as long as it binds to Arid5A.
- Bispecific antibody refers to an antibody having variable regions that recognize different epitopes in the same antibody molecule, but the epitope may exist in different molecules or in the same molecule. It may be. That is, in the present invention, the bispecific antibody can also have an antigen-binding site that recognizes a different epitope of Arid5A. It is also possible to use a bispecific antibody in which one recognition site recognizes Arid5A and the other recognition site recognizes an antigen other than Arid5A.
- bispecific antibodies can be produced by combining two types of antibodies with different recognition antigens.
- the antibody to be bound may be a half molecule of an antibody each having an H chain and an L chain, or may be a quarter molecule of an antibody consisting of only an H chain.
- bispecific antibody-producing fused cells can be prepared by fusing hybridomas that produce different monoclonal antibodies.
- bispecific antibodies can be produced by genetic engineering techniques.
- the antibody of the present invention may be a low molecular weight antibody as long as it binds to Arid5A.
- the low molecular weight antibody includes an antibody fragment in which a part of a full-length antibody (a whole antibody, such as a whole IgG) is deleted. As long as it binds to Arid5A, partial deletion of the antibody molecule is tolerated.
- the antibody fragment in the present invention preferably contains either or both of a heavy chain variable region (VH) and a light chain variable region (VL).
- VH heavy chain variable region
- VL light chain variable region
- the amino acid sequence of VH or VL can include additions, deletions and / or substitutions. Furthermore, as long as it binds to Arid5A, either or both of VH and VL can be deleted.
- the antibody fragment may be chimerized or humanized.
- Specific examples of the antibody fragment include Fab, Fab ′, F (ab ′) 2, Fv and the like.
- Specific examples of the low molecular weight antibody include, for example, Fab, Fab ′, F (ab ′) 2, Fv, scFv (single-chain Fv), diabody (Diabody), sc (Fv) 2 (single- chain (Fv) 2).
- Multimers eg, dimers, trimers, tetramers, polymers
- Antibody fragments can be generated by digesting antibodies with enzymes.
- enzymes that produce antibody fragments include, for example, papain, pepsin, and plasmin.
- DNA encoding these antibody fragments can be constructed, introduced into an expression vector, and then expressed in an appropriate host cell (for example, Co MS et al., J. Immunol. (1994) 152). , 2968-2976, Better M. & Horwitz A. H., Methods in Enzymology (1989) 178, 476-496, Puckthun A. & Skerra A., Methods in Enzymology, (1989) 15L4, 1989-157 , Methods in Enzymology (1986) 121, 652-663, Rousseaux J. et al., Methods in Enzymology (1986) 121, 663-669, ird R.E. & Walker B.W., Trends Biotechnol. (1991) 9,132-137).
- a digestive enzyme cleaves an antibody at a specific position to give an antibody fragment having a specific structure as follows.
- any part of the antibody can be deleted: Papain digestion: Fab; Pepsin digest: F (ab ′) 2 or F (ab ′); Plasmin digestion: Facb.
- ScFv is obtained by linking antibody VH and VL.
- VH and VL are linked via a linker, preferably a peptide linker (Huston JS et al., Proc. Natl. Acad. Sci. USA (1988) 85, 5879-5883).
- VH and VL in scFv may be derived from any of the antibodies described herein as antibodies.
- any single chain peptide consisting of about 3 to 25 residues can be used as a linker.
- V regions can be linked by, for example, the PCR method as described above.
- DNA sequence encoding antibody H chain or H chain V region and all or desired partial amino acid sequence of DNA sequence encoding antibody L chain or L chain V region The encoding DNA is used as a template.
- DNAs encoding the V regions of the H chain and the L chain are each amplified by PCR using primers having sequences corresponding to the sequences at both ends of the DNA to be amplified.
- DNA encoding a peptide linker moiety is prepared.
- DNA encoding a peptide linker can also be synthesized using PCR.
- the assembly PCR primer is a primer set capable of amplifying DNA encoding the full-length sequence of scFv to be synthesized.
- a base sequence that can be linked to each V region DNA is added to [peptide linker DNA].
- these DNAs are ligated, and the full length of scFv is finally generated as an amplification product by the primer for assembly PCR.
- an expression vector containing them and a recombinant cell transformed with the expression vector can be obtained according to a conventional method. Further, the scFv can be obtained by culturing the resulting recombinant cells and expressing the DNA encoding the scFv.
- Diabodies refer to bivalent low molecular weight antibodies constructed by gene fusion (Holliger P. et al., Proc. Natl. Acad. Sci. USA (1993) 90, 6444-6448, EP 404097, WO 93 / 11161). Diabodies are dimers composed of two polypeptide chains. Usually, in the polypeptide chain constituting the dimer, VL and VH are connected to each other by a linker in the same chain.
- the polypeptide chain linker in the diabody is generally short enough that VL and VH in the same chain cannot bind to each other.
- the amino acid residues constituting the linker are preferably 2 to 12 residues, more preferably 3 to 10 residues, and particularly about 5 residues. Therefore, VL and VH encoded on the same polypeptide chain cannot form scFv, but dimerize so as to form two Fvs between different polypeptide chains. As a result, the diabody has two antigen binding sites.
- sc (Fv) 2 is a low molecular weight antibody in which two VHs and two VLs are linked to form a single chain by a linker (Hudson PJ & Kortt AA, J. Immunol. Methods ( 1999) 231, 177-189).
- sc (Fv) 2 can be prepared, for example, by linking two scFvs with a linker.
- two VH and two VL with a linker starting from the N-terminal side of the single-chain polypeptide, [VH]-[Linker]-[VL]-[Linker]-[VH]-[Linker]-[VL] It can also be produced by tying in the order of.
- the order of the two VHs and the two VLs is not particularly limited to the above arrangement, and may be arranged in any order. For example, the following arrangements can also be mentioned.
- any peptide linker that can be introduced by genetic engineering, or a synthetic compound linker (for example, a linker disclosed in Protein Engineering (1996) 9, 299-305) or the like may be used. it can.
- a peptide linker is preferred.
- the length of the peptide linker is not particularly limited, and can be appropriately selected by those skilled in the art according to the purpose.
- the amino acid residue constituting the peptide linker is 1 to 100 amino acids, preferably 3 to 50 amino acids, more preferably 5 to 30 amino acids, particularly preferably 12 to 18 amino acids (for example, 15 amino acids).
- the amino acid sequence constituting the peptide linker can be any sequence as long as it does not inhibit the scFv binding action.
- the V regions can be linked using a synthetic chemical linker (chemical crosslinking agent).
- a crosslinking agent usually used for crosslinking such as peptide compounds can be used in the present invention.
- a crosslinking agent usually used for crosslinking such as peptide compounds can be used in the present invention.
- the Arid5A inhibitor used in the present invention has the general formula: Or a pharmaceutically acceptable salt thereof. Chlorpromazine also inhibits IL-6 mRNA expression through inhibition of Arid5A expression, specifically inhibiting IL-6 mRNA stabilization.
- a septic and / or septic shock therapeutic or preventive agent may be added with pharmaceutically acceptable materials such as preservatives and stabilizers.
- “Pharmaceutically acceptable” may be a material that itself has a therapeutic effect on sepsis and / or septic shock, or may be a material that does not have the therapeutic effect. It means a pharmaceutically acceptable material that can be administered together. Moreover, it is a material which does not have a therapeutic effect, Comprising: The material which has a synergistic effect or an additive stabilization effect by using together with an Arid5A inhibitor may be sufficient.
- Examples of materials that are acceptable for formulation include sterilized water, physiological saline, preservatives, stabilizers, excipients, buffers, preservatives, surfactants, chelating agents (EDTA, etc.), binders, and the like. Can do.
- examples of the surfactant include nonionic surfactants such as sorbitan fatty acid esters such as sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate; glycerin monocaprylate, glycerin monomylate.
- nonionic surfactants such as sorbitan fatty acid esters such as sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate; glycerin monocaprylate, glycerin monomylate.
- Typical examples include those having HLB 6-18 such as glycerin fatty acid ester such as glycerin monostearate.
- surfactant examples include anionic surfactants such as alkyl sulfates having an alkyl group having 10 to 18 carbon atoms such as sodium cetyl sulfate, sodium lauryl sulfate, and sodium oleyl sulfate; polyoxyethylene Polyoxyethylene alkyl ether sulfates having an average addition mole number of ethylene oxide of 2 to 4 and an alkyl group of 10 to 18 carbon atoms such as sodium lauryl sulfate; Carbon atoms of the alkyl group such as sodium lauryl sulfosuccinate Typical examples include alkylsulfosuccinic acid ester salts having 8 to 18 numbers; natural surfactants such as lecithin, glycerophospholipid; fingophospholipids such as sphingomyelin; and sucrose fatty acid esters of fatty acids having 12 to 18 carbon atoms. Can be mentioned.
- anionic surfactants such as alkyl sulfates having an
- Preferred surfactants for use in the formulations of the present invention are polyoxyethylene sorbitan fatty acid esters such as polysorbate 20, 40, 60 or 80, with polysorbates 20 and 80 being particularly preferred.
- Polyoxyethylene polyoxypropylene glycol represented by poloxamer such as Pluronic F-68 (registered trademark) is also preferable.
- buffering agent phosphoric acid, citric acid buffer, acetic acid, malic acid, tartaric acid, succinic acid, lactic acid, potassium phosphate, gluconic acid, caprylic acid, deoxycholic acid, salicylic acid, triethanolamine, fumaric acid Other organic acids, etc., or carbonate buffer, Tris buffer, histidine buffer, imidazole buffer and the like can be mentioned.
- a solution formulation may be prepared by dissolving in an aqueous buffer known in the field of solution formulation.
- concentration of the buffer is generally 1 to 500 mM, preferably 5 to 100 mM, and more preferably 10 to 20 mM.
- the drug in the present invention may contain other low molecular weight polypeptides, proteins such as serum albumin, gelatin and immunoglobulin, saccharides such as amino acids, polysaccharides and monosaccharides, carbohydrates, and sugar alcohols.
- proteins such as serum albumin, gelatin and immunoglobulin
- saccharides such as amino acids, polysaccharides and monosaccharides, carbohydrates, and sugar alcohols.
- saccharides and carbohydrates such as polysaccharides and monosaccharides include dextran, glucose, fructose, lactose, xylose, mannose, maltose, sucrose, trehalose, and raffinose.
- examples of the sugar alcohol include mannitol, sorbitol, inositol and the like.
- the drug in the present invention is an aqueous solution for injection
- isotonic solutions containing physiological saline, glucose and other adjuvants (for example, D-sorbitol, D-mannose, D-mannitol, sodium chloride).
- a suitable solubilizer such as alcohol (ethanol, etc.), polyalcohol (propylene glycol, PEG, etc.), nonionic surfactant (polysorbate 80, HCO-50), etc.
- it may further contain a diluent, a solubilizer, a pH adjuster, a soothing agent, a sulfur-containing reducing agent, an antioxidant and the like.
- the drug in the present invention is encapsulated in microcapsules (microcapsules such as hydroxymethylcellulose, gelatin, poly [methylmethacrylic acid]) or colloid drug delivery systems (liposomes, albumin microspheres, microemulsions, nanocapsules). Particles and nanocapsules, etc. (see “Remington's Pharmaceutical Science 16th edition”, Oslo Ed., 1980, etc.).
- a method of making a drug a sustained-release drug is also known and can be applied to the present invention (Langer et al., J. Biomed. Mater. Res. 1981, 15: 167-277; Langer, Chem. Tech. 1982, 12: 98-105; US Pat. No.
- the pharmaceutically acceptable carrier to be used is selected appropriately or in combination from the above depending on the dosage form, but is not limited thereto.
- the Arid5A inhibitor of the present invention when used as a medicine for humans or other animals, in addition to directly administering these substances to a patient, it can also be formulated and administered by a known pharmaceutical method. It is. In the case of formulation, the above-described formulation-acceptable materials may be added.
- All drugs in the present invention can be administered in the form of pharmaceuticals, and can be administered systemically or locally orally or parenterally.
- intravenous injection such as infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppository, enema, oral enteric solvent, etc.
- the effective dose is selected in the range of 0.001 mg to 100 mg per kg of body weight per time.
- a dose of 0.1 to 1000 mg, preferably 0.1 to 50 mg per patient can be selected.
- an effective dose is an effective dose such that an amount of free antibody is present in the blood.
- the administration schedule is 2 times / week or once / week to once / 2 weeks, once / 3 weeks, once / 4 weeks, etc. while observing the state after administration and observing the trend of blood test values It is also possible to adjust such as extending the administration interval.
- the present invention relates to a method for screening candidate substances useful for the treatment or prevention of sepsis and / or septic shock by suppressing the expression and / or function of Arid5A.
- the screening method is: (A) a step of evaluating the influence of the test substance on the expression and / or function of Arid5A, and (b) a process of selecting a substance that decreases the expression and / or function of Arid5A compared to the case where the test substance is not used. , And comprising.
- the screening method of the present invention first comprises evaluating the influence of the test substance on the expression and / or function of Arid5A.
- the function of Arid5A is to stabilize IL-6 mRNA by, for example, binding specifically to the stem loop of IL-6 mRNA and competitively inhibiting the action of Regnase-1 that specifically destroys IL-6 mRNA.
- the effects on the expression and / or function of Arid5A include, for example, suppressing the expression of Arid5A, inhibiting the function of Arid5A by binding to Arid5A, and binding to IL-6 mRNA competitively with Arid5A Examples include, but are not limited to, inhibiting the function of Arid5A.
- the process of selecting the substance which reduces the expression and / or function of this Arid5A compared with the case where a test substance is not used is included.
- Arid5A is contacted with a test substance.
- Arid5A used in the method of the present invention includes proteins functionally equivalent to the above-mentioned known Arid5A.
- proteins include, but are not limited to, Arid5A mutants, alleles, variants, homologs, Arid5A partial peptides, or fusion proteins with other proteins.
- the variant of Arid5A in the present invention is a naturally occurring protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence described above, and the amino acid described above
- a protein functionally equivalent to a protein consisting of a sequence can be mentioned.
- a protein encoded by a naturally derived DNA that hybridizes under stringent conditions with a DNA comprising the aforementioned base sequence, and a protein functionally equivalent to a protein comprising the aforementioned amino acid sequence It can be mentioned as a variant of Arid5A.
- the number of amino acids to be mutated is not particularly limited, but is usually within 30 amino acids, preferably within 15 amino acids, and more preferably within 5 amino acids (for example, within 3 amino acids).
- the amino acid residue to be mutated is preferably mutated to another amino acid in which the properties of the amino acid side chain are conserved.
- amino acid side chain properties include hydrophobic amino acids (A, I, L, M, F, P, W, Y, V) and hydrophilic amino acids (R, D, N, C, E, Q, G).
- “functionally equivalent” means that the target protein has a biological function or biochemical function equivalent to Arid5A.
- Arid5A specifically binds to the stem loop of IL-6 mRNA and contributes to stabilization of IL-6 mRNA by antagonistically inhibiting the action of Regnase-1 that specifically destroys IL-6 mRNA.
- the biological function and biochemical function of Arid5A include stabilization of IL-6 mRNA.
- DNA encoding a “functionally equivalent protein” of the target protein methods well known to those skilled in the art include methods using hybridization technology or polymerase chain reaction (PCR) technology. It is done. That is, for those skilled in the art, DNA having high homology with Arid5A is usually isolated using the base sequence of Arid5A or a part thereof as a probe, and an oligonucleotide that specifically hybridizes to Arid5A as a primer. That is. Thus, DNA encoding a protein having a function equivalent to Arid5A that can be isolated by hybridization technology or PCR technology is also included in the DNA of the present invention.
- PCR polymerase chain reaction
- a hybridization reaction is preferably performed under stringent conditions.
- stringent hybridization conditions refer to hybridization of 6M urea, 0.4% SDS, 0.5 ⁇ SSC or equivalent stringency. Isolation of DNA with higher homology can be expected by using conditions with higher stringency, for example, 6M urea, 0.4% SDS, 0.1 ⁇ SSC.
- the isolated DNA is considered to have high homology with the amino acid sequence of the target protein at the amino acid level. High homology means a sequence of at least 50% or more, more preferably 70% or more, more preferably 90% or more (for example, 95%, 96%, 97%, 98%, 99% or more) in the entire amino acid sequence.
- the biological species from which Arid5A used in the method of the present invention is derived is not limited to a specific biological species.
- human, monkey, mouse, rat, guinea pig, pig, cow, yeast, insect and the like can be mentioned.
- the state of Arid5A used in the first embodiment is not particularly limited, and may be, for example, a purified state, a state expressed in a cell, a state expressed in a cell extract, or the like.
- the purification of Arid5A can be performed by a known method.
- Examples of cells expressing Arid5A include cells expressing endogenous Arid5A and cells expressing exogenous Arid5A.
- Examples of the cells expressing the endogenous Arid5A include, but are not limited to, cells derived from animal tissues and cultured cells.
- the cultured cells are not particularly limited, and for example, commercially available cells can be used.
- the biological species from which cells expressing endogenous Arid5A are derived is not particularly limited and includes humans, monkeys, mice, rats, guinea pigs, pigs, cows, yeasts, insects and the like.
- the exogenous Arid5A-expressing cell can be prepared, for example, by introducing a vector containing DNA encoding Arid5A into the cell. Introduction of the vector into the cells can be performed by a general method such as calcium phosphate precipitation, electric pulse perforation, lipofectamine method, microinjection method and the like.
- the exogenous Arid5A-containing cells can be prepared, for example, by inserting DNA encoding Arid5A into a chromosome by a gene transfer method using homologous recombination.
- the biological species from which the cells into which such exogenous Arid5A is introduced are not limited to mammals, and may be any biological species for which a technique for expressing foreign proteins in the cells has been established.
- examples of the cell extract in which Arid5A is expressed include, for example, those obtained by adding a vector containing DNA encoding Arid5A to a cell extract contained in an in vitro transcription / translation system.
- the in vitro transcription / translation system is not particularly limited, and a commercially available in vitro transcription / translation kit can be used.
- test substance in the present invention is not particularly limited.
- a single substance such as a natural compound, an organic compound, an inorganic compound, a nucleic acid, a protein, a peptide, and a compound library, a nucleic acid library, and a peptide library
- gene library expression products include gene library expression products, cell extracts, cell culture supernatants, fermented microorganism products, marine organism extracts, plant extracts, prokaryotic cell extracts, eukaryotic single cell extracts or animal cell extracts, etc. Can do.
- the test substance can be appropriately labeled and used as necessary. Examples of the label include a radiolabel and a fluorescent label. Further, in addition to the test substance, a mixture obtained by mixing a plurality of these test substances is also included.
- “contact” is performed according to the state of Arid 5A.
- Arid5A if Arid5A is in a purified state, it can be carried out by adding a test substance to the purified preparation.
- the test substance if it is expressed in a cell or in a cell extract, the test substance is added to the cell culture solution or cell extract, or the test substance is administered directly to the experimental animal, respectively. This can be done.
- the test substance is a protein
- a vector containing DNA encoding the protein is introduced into a cell expressing Arid5A, or the vector is added to a cell extract expressing Arid5A. It is also possible to do this.
- a two-hybrid method using yeast or animal cells can be used.
- the influence of the test substance on the expression and / or function of the test substance is then evaluated by measuring the expression and / or function of Arid5A.
- the function of Arid5A can include stabilization of IL-6 mRNA.
- the function of Arid5A can be indirectly measured by coexisting Arid5A and a test substance and measuring the degradation inhibitory effect of IL-6 mRNA. Then, a test substance that reduces the expression and / or function of Arid5A is selected as compared with the case where the test substance is not contacted.
- PCR polymerase chain reaction
- RT-PCR reverse transcription-chainase chain reaction
- real-time PCR-based techniques hybridization-based techniques, and / or other detection techniques. Etc. can be appropriately selected.
- PCR in the present application includes a method for measuring various DNAs, RNAs, and the like by a technique based on PCR and amplification derived therefrom.
- Arid5A is a protein that contributes to the stabilization of IL-6 mRNA
- IL-6 mRNA expression is suppressed, but TNF- ⁇ mRNA expression is suppressed. Is known to have no effect. Therefore, by confirming that the test substance affects the expression of IL-6 mRNA but does not affect the expression of TNF- ⁇ mRNA, a substance that affects the expression of Arid5A, ie, As a result, it is possible to screen a substance having an effect of treating or preventing sepsis and / or septic shock.
- the selected test substance includes a substance that decreases the expression and / or function of Arid5A, and thereby suppresses the expression and / or function of Arid5A, thereby treating or preventing sepsis and / or septic shock. It is thought that it shows the effect to do.
- the test substance is first brought into contact with Arid5A, and then the binding between Arid5A and the test substance is detected to evaluate the influence of the test substance on the expression and / or function of Arid5A.
- the binding between Arid5A and the test substance can be detected by, for example, a label attached to the test substance bound to Arid5A (for example, a label capable of quantitative measurement such as a radiolabel or a fluorescent label).
- a labeling agent can also be bound to Arid5A. Binding can also be detected by immobilizing a test substance or Arid5A on a resin or chip.
- a change in the function of Arid5A caused by the binding of the test substance to Arid5A can also be detected as an index.
- a test substance that binds to Arid5A is then selected.
- the selected substance includes a substance that decreases the expression or function of Arid5A as compared to the case where the test substance is not contacted.
- the test substance is first brought into contact with cells expressing Arid5A, and then the expression level of Arid5A is measured to evaluate the influence of the test substance on the expression of Arid5A.
- the expression level of Arid5A can be measured by methods known to those skilled in the art.
- the transcription level of the gene can be measured by extracting mRNA of the gene according to a standard method and performing Northern hybridization or RT-PCR using the mRNA as a template.
- the expression level of the gene can be measured using DNA array technology.
- a fraction containing Arid5A encoded by the gene can be collected according to a standard method, and the expression level of the Arid5A can be detected by electrophoresis such as SDS-PAGE to measure the translation level of the gene.
- electrophoresis such as SDS-PAGE
- the antibody against Arid5A those described above can be used.
- a test substance having a reduced expression level of Arid5A is then selected as compared with the case where the test substance is not contacted.
- the selected substance includes a substance that decreases the expression of Arid5A, and suppressing the expression of Arid5A is considered to exhibit an effect of treating or preventing sepsis and / or septic shock as a result.
- Arid5A is a protein that contributes to the stabilization of IL-6 mRNA, when Arid5A expression is inhibited in the cell, IL-6 mRNA expression is suppressed, but TNF- ⁇ mRNA is suppressed. It is known that expression is not affected.
- test substance affects the expression of IL-6 mRNA but does not affect the expression of TNF- ⁇ mRNA
- a substance that affects the expression of Arid5A ie
- a cell or a cell extract having DNA having a reporter gene operably linked downstream of the promoter region of DNA encoding Arid5A is first provided.
- “functionally linked” means that the transcriptional factor binds to the promoter region of the Arid5A gene so that expression of the reporter gene is induced, and the promoter region of the Arid5A gene and the reporter gene Is connected. Therefore, even when the reporter gene is bound to another gene and forms a fusion protein with another gene product, the expression of the fusion protein is caused by the transcription factor binding to the promoter region of the Arid5A gene. If it is derived, it is included in the meaning of the above “functionally coupled”.
- the reporter gene is not particularly limited as long as its expression can be detected.
- a CAT gene, a lacZ gene, a luciferase gene, a ⁇ -glucuronidase gene (GUS) and a GFP that are commonly used by those skilled in the art.
- a gene etc. can be mentioned.
- the reporter gene also includes DNA encoding Arid5A.
- a cell or cell extract having a DNA to which a reporter gene is operably linked downstream of the promoter region of DNA encoding Arid5A can be prepared by the method described above.
- test substance is then brought into contact with the cells or the cell extract. Subsequently, the influence of the test substance on the expression of Arid5A is evaluated by measuring the expression level of the reporter gene in the cell or the cell extract.
- the expression level of the reporter gene can be measured by methods known to those skilled in the art depending on the type of reporter gene used. For example, when the reporter gene is a CAT gene, the expression level of the reporter gene can be measured by detecting acetylation of chloramphenicol by the gene product. When the reporter gene is a lacZ gene, the color of the dye compound is detected by the catalytic action of the gene expression product. When the reporter gene is a luciferase gene, the fluorescence of the fluorescent compound by the catalytic action of the gene product is detected.
- the expression level of the gene can be measured by the method described above.
- a test substance that decreases or increases the expression level of the reporter gene is then selected as compared with the case where the test substance is not contacted.
- the selected substance includes a substance that decreases the expression of Arid5A, and suppressing the expression of Arid5A is considered to have an effect of treating or preventing sepsis and / or septic shock as a result.
- the test substance is first brought into contact with IL-6 mRNA, and then the binding of IL-6 mRNA to the test substance is detected to evaluate the influence of the test substance on the expression and / or function of Arid5A.
- the binding between IL-6 mRNA and the test substance can be detected by, for example, a label attached to the test substance bound to IL-6 mRNA (for example, a label capable of quantitative measurement such as a radiolabel or a fluorescent label).
- a labeling agent can also be bound to IL-6 mRNA. Binding can also be detected by immobilizing a test substance or IL-6 mRNA on a resin or chip.
- Changes in the activity of IL-6 mRNA caused by binding of a test substance to IL-6 mRNA can also be detected as an indicator.
- a test substance that binds to IL-6 mRNA is then selected.
- the selected substance includes a substance that decreases the expression and / or function of Arid5A. By suppressing the expression or function of Arid5A, the substance exhibits an effect of treating or preventing sepsis and / or septic shock as a result. It is considered a thing.
- the test substance is first contacted with IL-6 mRNA, then Arid5A is further contacted, and then the function of Arid5A is measured to evaluate the effect on the function of Arid5A.
- the function of Arid5A can be measured as described above.
- a test substance having a reduced function as compared with the case where the test substance is not contacted is selected.
- the selected test substance includes a substance that decreases the function of Arid5A, and suppressing the function of Arid5A is considered to exhibit an effect of treating or preventing sepsis and / or septic shock as a result.
- the test substance is first administered to an experimental animal, and further, the influence on the expression of Arid5A is measured by PCR, and then the expression of Arid5A is reduced as compared with the case where the test substance is not administered to the experimental animal.
- Administration to experimental animals and measurement by PCR are as described above.
- Example 1 Generation of Arid5A knockout mouse (FIG. 1) C57BL / 6 wild type mice (6-8 weeks) were obtained from CLEA, and Arid5A knockout mice (No. CDB0602K: www.cdb.riken.jp/arg/mutant%20mice%20list.html ) were obtained from www.cdb. It was prepared by the method of riken.jp/arg/Methods.html .
- Example 2 Septic shock in Arid5A knockout mice Escherichia coli sera were obtained from type 0127: B8 against 8-9 week old Arid5A knockout mice (Arid5A-/-) and wild type mice (body weight 18-20 g, respectively). The obtained LPS (Sigma-Aldrich) was administered intraperitoneally and the mortality was observed for 7 days.
- an anti-IL-6 receptor antibody MR16-1 antibody, 250 mg / kg
- an anti-IFN ⁇ antibody R4-6A2 BioLegend, 25 mg / kg
- mice administered with wild type, IL-6 receptor antibody, and TNF antibody died, whereas Arid5A knockout mice did not develop septic shock.
- Arid5A siRNA (SASI_Mm02_00341523 (sigma)) or control siRNA (100 nM) was introduced into the mouse macrophage cell line RAW264.7 by electroporation. After culturing for 24 hours, the cells were stimulated with LPS (100 ng / mL) for 24 hours, and RNA was extracted from the obtained cells. The mRNA level of Arid5A was quantified by qPCR (FIG. 3). In addition, the concentrations of IL-6 and TNF- ⁇ in each culture supernatant were quantified by ELISA (FIGS. 4 and 5). As shown in FIG.
- Example 4 Screening method of candidate substances useful for treatment of sepsis and / or septic shock C57BL / 6 mice (6 to 8 weeks old) peritoneal macrophages in the presence or absence of a test substance (20 ⁇ M) Stimulated with LPS (1 ⁇ g / mL).
- the relative expression levels of Arid5A, IL-6 and TNF- ⁇ mRNA in the stimulated peritoneal macrophages were measured by quantitative PCR (qPCR).
- qPCR quantitative PCR
- For Arid5A mRNA the expression level was measured 2 hours after LPS stimulation, and for IL-6 mRNA and TNF- ⁇ mRNA 2 hours, 6 hours, 12 hours, and 24 hours after LPS stimulation.
- the results of using chlorpromazine (CPZ) as a test substance are shown in FIGS.
- CPZ is a substance that inhibits the expression of Arid5A mRNA itself.
- CPZ is a substance that also inhibits the expression of IL-6 mRNA affected by Arid5A, and has no effect on TNF- ⁇ mRNA that is known not to be affected by Arid5A. It was a substance. This suggests that CPZ is a substance that specifically inhibits IL-6 mRNA stabilization and is effective in the treatment of sepsis and / or septic shock involving inflammatory cytokines such as IL-6. It was done.
- Arid5A intracellular Arid5A mRNA
- a substance that inhibits the action of Arid5A can be efficiently screened by screening a substance that inhibits the expression of mRNA but does not affect the mRNA of TNF- ⁇ .
- a substance effective for the treatment of sepsis and / or septic shock can be efficiently screened.
- a pharmaceutical composition having a high therapeutic effect on sepsis and septic shock is provided by the therapeutic agent for sepsis and / or septic shock of the present invention.
- the present invention can provide a screening method for a therapeutic agent exhibiting a high therapeutic effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、より有効な敗血症及び/又は敗血症性ショックの治療剤、並びにそのスクリーニング方法を提供することを目的とする。
〔1〕Arid5A阻害剤を有効成分とする、敗血症及び/又は敗血症性ショック治療剤である。
〔2〕Arid5A阻害剤が、核酸オリゴ、及びArid5A抗体からなる群より選ばれる1種以上の物質である、〔1〕記載の敗血症及び/又は敗血症性ショック治療剤である。
〔3〕核酸オリゴが、天然及び非天然のRNAまたはDNAからなるオリゴである、〔2〕記載の敗血症及び/又は敗血症性ショック治療剤である。
〔4〕敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの発現及び/又は機能に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの発現及び/又は機能を減少させる物質を選択する工程、
とを含んでなる方法である。
〔5〕〔4〕に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの発現に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの発現を減少させる物質を選択する工程、
とを含んでなる方法である。
〔6〕〔4〕に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質を、実験動物に投与する工程、
(b)該Arid5Aの発現に対する影響についてPCRにて測定する工程、及び
(c)被験物質を実験動物に投与しない場合と比較して、Arid5Aを減少させる物質を選択する工程、
とを含んでなる方法である。
〔7〕〔4〕に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの機能に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの機能を減少させる物質を選択する工程、
とを含んでなる方法である。
〔8〕〔7〕に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該Arid5Aの機能がIL-6mRNAの安定化である方法である。
〔9〕Arid5A阻害剤を投与することを含んでなる、敗血症及び/又は敗血症性ショックの治療方法である。
〔10〕敗血症及び/又は敗血症性ショックの治療に使用するためのArid5A阻害剤である。
〔11〕敗血症及び/又は敗血症性ショックの治療剤の製造のためのArid5A阻害剤の使用である。
本発明は、敗血症および/又は敗血症性ショック治療剤、並びにそのスクリーニング方法に関する。本発明の敗血症および/又は敗血症性ショック治療剤は、Arid5A阻害剤を有効成分とする。
原核細胞を使用する場合、細菌細胞を用いる産生系がある。細菌細胞としては、大腸菌(E.coli)、枯草菌が知られている。
一方、in vivoの産生系としては、動物を使用する産生系や植物を使用する産生系が挙げられる。動物を使用する場合、哺乳類動物、昆虫を用いる産生系などがある。
パパイン消化:Fab;
ペプシン消化:F(ab')2またはF(ab');
プラスミン消化:Facb。
[VH]-[リンカー]-[VL]-[リンカー]-[VH]-[リンカー]-[VL]
の順に結ぶことによっても作製できる。なお2つのVHと2つのVLの順序は特に上記配置に限定されず、どのような順序で並べられていてもよい。例えば以下のような配置も挙げることができる。
[VL]-[リンカー]-[VH]-[リンカー]-[VH]-[リンカー]-[VL]
[VH]-[リンカー]-[VL]-[リンカー]-[VL]-[リンカー]-[VH]
[VH]-[リンカー]-[VH]-[リンカー]-[VL]-[リンカー]-[VL]
[VL]-[リンカー]-[VL]-[リンカー]-[VH]-[リンカー]-[VH]
[VL]-[リンカー]-[VH]-[リンカー]-[VL]-[リンカー]-[VH]
複数のリンカーは、同じ種類のリンカーであってもよいし、異なる種類のリンカーであってもよい。
で表されるクロルプロマジン又はその医薬上許容しうる塩を含む。クロルプロマジンは、Arid5A発現の阻害を介してIL-6のmRNAの発現も阻害し、IL-6のmRNAの安定化を特異的に阻害する。
所望によりさらに希釈剤、溶解補助剤、pH調整剤、無痛化剤、含硫還元剤、酸化防止剤等を含有してもよい。
使用される製剤上許容しうる担体は、剤型に応じて上記の中から適宜あるいは組合せて選択されるが、これらに限定されるものではない。
(a)被験物質のArid5Aの発現及び/又は機能に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの発現及び/又は機能を減少させる物質を選択する工程、
とを含んでなる。
また、被験物質を用いない場合と比較して、該Arid5Aの発現および/または機能を減少させる物質を選択する工程を含む。
本態様では、次いで、Arid5Aと結合する被験物質を選択する。選択された物質には、被験物質を接触させない場合と比較して、Arid5Aの発現または機能を減少させる物質が含まれ、Arid5Aの発現または機能を抑制することによって、結果的に敗血症および/または敗血症性ショックを治療または予防する効果を示すものと考えられる。
第四の態様において、「機能的に結合した」とは、Arid5A遺伝子のプロモーター領域に転写因子が結合することにより、レポーター遺伝子の発現が誘導されるように、Arid5A遺伝子のプロモーター領域とレポーター遺伝子とが結合していることをいう。従って、レポーター遺伝子が他の遺伝子と結合しており、他の遺伝子産物との融合タンパク質を形成する場合であっても、Arid5A遺伝子のプロモーター領域に転写因子が結合することによって、該融合タンパク質の発現が誘導されるものであれば、上記「機能的に結合した」の意に含まれる。
Arid5AをコードするDNAのプロモーター領域の下流にレポーター遺伝子が機能的に結合したDNAを有する細胞または細胞抽出液は、上述の方法にて調製することが可能である。
本態様では、次いで、IL-6mRNAと結合する被験物質を選択する。選択された物質にはArid5Aの発現および/または機能を減少させる物質が含まれ、Arid5Aの発現または機能を抑制することによって、結果的に敗血症および/または敗血症性ショックを治療または予防する効果を示すものと考えられる。
CLEA社からC57BL/6野生型マウス(6-8週)を入手し、Arid5Aノックアウトマウス(No.CDB0602K:www.cdb.riken.jp/arg/mutant%20mice%20list.html)をwww.cdb.riken.jp/arg/Methods.htmlの方法により作製した。Arid5A遺伝子のDNA結合ドメインの主要部分を、両端をloxP配列で挟んだNeo-cassetteによって置換するように構築したターゲッティングベクターを、TT2株ES細胞にエレクトロポレーション法により導入した。相同的組み換えによる遺伝子破壊は、Arid5Aの遺伝子の3’UTRに対するプローブを使用したサザンブロッティング法により確認し、得られた変異ES細胞を用いてキメラマウスを作製した。変異アレルのジャームライントランスミッションの確認は、キメラマウスをC57BLマウスと交配して得られた次世代のマウスのゲノムDNAを用いた、サザンブロッティング解析およびゲノムPCR(プライマー1:5’-ATACTTTCTCGGCAGGAGCA-3’;プライマー2:5’-TGAATGAACTGCAGGACGAG-3’)により行った。ヘテロ接合型の変異マウスは特定病原体のフリーの環境下で飼育し、C57BLマウスと5回の戻し交配を行った。
8~9週齢のArid5Aノックアウトマウス(Arid5A-/-)及び野生型マウス(それぞれ体重18-20g)に対し、Escherichia coli血清を型0127:B8から得られたLPS(シグマ-アルドリッチ社)を腹腔内に投与し、7日間死亡率を観察した。また、LPS投与4時間後にIL-6とIFNγの役割を調べるために抗IL-6受容体抗体(MR16-1抗体、250mg/kg)、抗IFNγ抗体(R4-6A2 BioLegend, 25mg/kg)を投与し、7日間死亡率を観察した。
その結果、野生型、IL-6受容体抗体、TNF抗体を投与したマウスは死亡したのに対し、Arid5Aノックアウトマウスでは敗血症性ショックが起こらなかった。
マウスマクロファージ細胞株RAW264.7に、Arid5AのsiRNA( SASI_Mm02_00341523 (sigma))又はコントロールのsiRNA(100nM)をエレクトロポレーション法にて導入した。24時間の培養後、細胞をLPS(100ng/mL)で24時間刺激し、得られた細胞からRNAを抽出した。Arid5AのmRNAレベルをqPCRによって定量した(図3)。また、それぞれの培養上清中のIL-6及びTNF-αの濃度をELISA法によって定量した(図4及び5)。図3に示す通り、RAW264.7にArid5AのsiRNAを導入したことにより、Arid5AのmRNA発現レベルが顕著に低下した。また、図4及び図5に示す通り、Arid5AのsiRNAを導入した細胞においては、LPS刺激によって産生されるIL-6の量が減少したのに対して、TNF-αの量には変化がなかった。
C57BL/6マウス(6~8週齢)の腹腔マクロファージを、被験物質(20μM)存在下又は非存在下において、LPS(1μg/mL)で刺激した。定量PCR(qPCR)によって、上記刺激した腹腔マクロファージにおけるArid5A、IL-6及びTNF-αのmRNAの相対発現レベルを測定した。Arid5AのmRNAについては、LPS刺激2時間後、IL-6のmRNA及びTNF-αのmRNAついては、LPS刺激2時間後、6時間後、12時間後、24時間後の発現レベルを測定した。被験物質として、クロルプロマジン(CPZ)を使用した結果を図6~8に示す。
Claims (11)
- Arid5A阻害剤を有効成分とする、敗血症及び/又は敗血症性ショック治療剤。
- Arid5A阻害剤が、核酸オリゴ、及びArid5A抗体からなる群より選ばれる1種以上の物質である、請求項1記載の敗血症及び/又は敗血症性ショック治療剤。
- 核酸オリゴが、天然及び非天然のRNAまたはDNAからなるオリゴである請求項2記載の敗血症及び/又は敗血症性ショック治療剤。
- 敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの発現及び/又は機能に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの発現及び/又は機能を減少させる物質を選択する工程、
とを含んでなる方法。 - 請求項4に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの発現に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの発現を減少させる物質を選択する工程、
とを含んでなる方法。 - 請求項4に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質を、実験動物に投与する工程、
(b)該Arid5Aの発現に対する影響についてPCRにて測定する工程、及び
(c)被験物質を実験動物に投与しない場合と比較して、Arid5Aの発現を減少させる物質を選択する工程、
とを含んでなる方法。 - 請求項4に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該方法は、
(a)被験物質のArid5Aの機能に対する影響を評価する工程、及び
(b)被験物質を用いない場合と比較して、Arid5Aの機能を減少させる物質を選択する工程、
とを含んでなる方法。 - 請求項7に記載の敗血症及び/又は敗血症性ショックの治療に有用な候補物質のスクリーニング方法であって、該Arid5Aの機能がIL-6mRNAの安定化である方法。
- Arid5A阻害剤を投与することを含んでなる、敗血症及び/又は敗血症性ショックの治療方法。
- 敗血症及び/又は敗血症性ショックの治療に使用するためのArid5A阻害剤。
- 敗血症及び/又は敗血症性ショックの治療剤の製造のためのArid5A阻害剤の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15873058.0A EP3251693B1 (en) | 2014-12-22 | 2015-12-22 | Novel therapeutic agent for septicemia, and a method for screening for same |
JP2016566382A JP6802067B2 (ja) | 2014-12-22 | 2015-12-22 | 新規な敗血症治療剤及び/又はそのスクリーニング方法 |
US15/537,985 US20180016576A1 (en) | 2014-12-22 | 2015-12-22 | Novel Therapeutic Agent for Septicemia, and a Method for Screening for Same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-259464 | 2014-12-22 | ||
JP2014259464 | 2014-12-22 | ||
JP2015083939 | 2015-04-16 | ||
JP2015-083939 | 2015-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016104490A1 true WO2016104490A1 (ja) | 2016-06-30 |
Family
ID=56150508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/085806 WO2016104490A1 (ja) | 2014-12-22 | 2015-12-22 | 新規な敗血症治療剤及び/又はそのスクリーニング方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20180016576A1 (ja) |
EP (1) | EP3251693B1 (ja) |
JP (1) | JP6802067B2 (ja) |
WO (1) | WO2016104490A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020241816A1 (ja) | 2019-05-31 | 2020-12-03 | 国立大学法人大阪大学 | 新規な消化器がん治療剤およびそのスクリーニング方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7258362B2 (ja) * | 2018-03-22 | 2023-04-17 | 国立大学法人京都大学 | 炎症抑制用の組成物 |
US10512639B1 (en) | 2019-04-28 | 2019-12-24 | King Faisal University | Therapeutic agents for treating diseases associated with chronic inflammation and screening method |
US20200338058A1 (en) | 2019-04-28 | 2020-10-29 | King Faisal University | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method |
US11001608B2 (en) | 2019-07-11 | 2021-05-11 | King Faisal University | Arid5a peptide inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004012A1 (en) * | 1994-08-05 | 1996-02-15 | Schering Corporation | Use of the combination of chlorpromazine plus interleukin-6 to treat or prevent septic shock |
-
2015
- 2015-12-22 US US15/537,985 patent/US20180016576A1/en not_active Abandoned
- 2015-12-22 JP JP2016566382A patent/JP6802067B2/ja active Active
- 2015-12-22 WO PCT/JP2015/085806 patent/WO2016104490A1/ja active Application Filing
- 2015-12-22 EP EP15873058.0A patent/EP3251693B1/en active Active
Non-Patent Citations (8)
Title |
---|
"Men'eki Nanbyo no Hassho Kiko no Kaimei ni Hitotsu no Kagi", OSAKA UNIVERSITY SAISHIN JOHO, 14 May 2013 (2013-05-14), XP009504182, Retrieved from the Internet <URL:http://www.osaka-u.ac.jp/ja/news/ResearchRelease/2013/05/20130514_1> [retrieved on 20160303] * |
GREENHILL, C. J. ET AL.: "IL -6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3", J. IMMUNOL., vol. 186, 2011, pages 1199 - 1208, XP055459955 * |
MAHABUB- UZ , Z. M. ET AL.: "Pathogenic role of Arid5a in endotoxin shock", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 44, 30 October 2015 (2015-10-30), pages 192, XP009504172 * |
MASUDA, K. ET AL.: "Arid5a controls IL -6 mRNA stability, which contributes to elevation of IL -6 level in vivo", PNAS, vol. 110, no. 23, 2013, pages 9409 - 9414, XP055343363 * |
RIEDEMANN, N. C. ET AL.: "Protective Effects of IL -6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression", J. IMMUNOL., vol. 170, 2003, pages 503 - 507, XP055459960 * |
SACHIKO TAKAMURA(AKASHI);: "Endotoxic Shock to TLR", INFLAMMATION & IMMUNOLOGY, vol. 13, no. 1, 2005, pages 37 - 44, XP009504168 * |
See also references of EP3251693A4 * |
TARAZONA. R ET AL.: "Chlorpromazine amplifies macrophage-dependent IL -10 production in vivo.", J. IMMUNOL., vol. 154, 1995, pages 861 - 870, XP055459941 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020241816A1 (ja) | 2019-05-31 | 2020-12-03 | 国立大学法人大阪大学 | 新規な消化器がん治療剤およびそのスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2016104490A1 (ja) | 2017-10-05 |
EP3251693A1 (en) | 2017-12-06 |
EP3251693A4 (en) | 2018-08-29 |
JP6802067B2 (ja) | 2020-12-16 |
EP3251693B1 (en) | 2022-11-02 |
US20180016576A1 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11279931B2 (en) | Therapeutic agent for a lung disease and/or method for screening for the same | |
JP5554993B2 (ja) | Anexelektoに結合するモノクローナル抗体、およびその利用 | |
KR101239051B1 (ko) | 심장질환 치료제 | |
JP5754875B2 (ja) | 筋再生促進剤 | |
JP6802067B2 (ja) | 新規な敗血症治療剤及び/又はそのスクリーニング方法 | |
JP5465231B2 (ja) | 調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法 | |
JPWO2009075344A1 (ja) | M−csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用 | |
JP6442404B2 (ja) | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 | |
JP7065786B2 (ja) | 肝病態を治療又は予防する方法 | |
JP6309050B2 (ja) | ヒトcrth2に特異的に結合する抗体 | |
WO2020213665A1 (ja) | Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 | |
WO2023243689A1 (ja) | 新規な炎症性疾患治療剤およびそのスクリーニング方法 | |
JP7128460B2 (ja) | Il-6阻害剤を有効成分とする精神疾患治療剤 | |
JP6714263B2 (ja) | 免疫調節剤及びスクリーニング方法 | |
WO2018074610A1 (ja) | Cd69アンタゴニストを含む劇症型急性肺炎治療用組成物 | |
KR20200074160A (ko) | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15873058 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016566382 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15537985 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015873058 Country of ref document: EP |